Open AccessZanubrutinib Shows Clinical Benefits in Waldenström Macroglobulinemia
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2020-0557
Subject(s) - medicine , macroglobulinemia , waldenstrom macroglobulinemia , intensive care medicine , immunology , multiple myeloma , lymphoma
In the head‐to‐head phase III ASPEN trial, zanubrutinib showed clinically meaningful improvements in safety and tolerability versus ibrutinib, with comparable efficacy, in patients with Waldenström macroglobulinemia.